| Prev Close | 3.38 |
| Day Low/High | 3.14 / 3.67 |
| 52 Wk Low/High | 0.80 / 6.25 |
MannKind Corporation (MNKD)
3.67
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 247.16B |
| Market Cap | 835.40M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Follow These Resolutions If You're Bargain Hunting for Sagging Biotech Stocks
These rules can help investors who are digging through the rubble that 2018 left behind in the biotech sector.
Mannkind Stock Drops Following Changes to Its Insulin Product
Mannkind stock is suffering, and the company appears to be in trouble.
Insulin Drug Offers Hope for MannKind
The stock has taken a beating, but users of Afrezza are loyal to the drug.
2016 Was a Terrible Year for Biotech but the Tweets Were on Point
2016 tweets by TheStreet's Adam Feuerstein kept us informed and entertained. From an unexpected twist on New Year's day with MannKind to J.P. Morgan's Healthcare conference to Bristol-Myers Squibb's oops!
What's Ahead for the Week: Can FedEx Deliver a Strong Quarter?
In 'What's Ahead on Wall Street' for the week of March 14, we have a mix of both earnings and economic data.
MannKind Investors Should Have Seen the Writing on the Wall
Shareholders should have been running from the drugmaker long before Tuesday's news that partner Sanofi was leaving first.
Is This One Giant Lurch for MannKind?
Meet the new (and likely temporary, 90-year-old) boss, same as the old boss.
Challenge to Readers: Value These 4 Stocks
Can a 'fair value' really be determined for the unprofitable Tesla, SunEdison, Plug Power and Mannkind?
Building a Sweet 16 Portfolio, Part 2
A little of this, a little of that to create a nice yield.
Building a Sweet 16 Portfolio, Part 1
Selection of stocks is tailor made for investor, given market parameters.
A Little Faith in MannKind
After an overly aggressive downgrade, is this a chance to buy?
EYES Has It
Second Sight's IPO was well received.
Fitz Bits: Do Not Try to Top-Tick
For now, just let the market do the heavy lifting for you.
Jim Cramer on Mannkind, Visa, FireEye and Linn Energy's Dividend
TheStreet's Jim Cramer is asked for advice on Mannkind, which has doubled in value after an FDA panel recommended approval of its insulin drug Afreeza.
MannKind Catches Fire While Zuckerberg, "Frozen" Stay Hot
Disney's 'Frozen' skated its way into history this week, becoming the highest-grossing animated movie ever with a total worldwide gross of $1.07 billion and counting.
Jim Cramer is Neutral on Mannkind's Afrezza Inhaled Insulin
TheStreet's Jim Cramer says he is completely neutral on Mannkind and sometimes it's better to admit you don't know where something is going.
Jobs Data, More GM Testimony and Mannkind Gets a Nod
ADP private payrolls data missed expectations for March, but the revision upward of February's number seemed to slightly satisfy traders.
Day Ahead: Riding the Wave Higher
Futures poised to extend gains; MannKind shares double.
